Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | VCAM1 | P19320 | 6/20 | 0.44 |
| ▸ | PPIA | P62937 | 1/20 | 0.44 |
| ▸ | PGK1 | P00558 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL864500 | 0.91 | TSHR (0.50) | TSHRMAPK1CYP3A4ALDH1A1VCAM1 | |
| SCHEMBL29721556 | 0.91 | TSHR (0.50) | TSHRMAPK1CYP3A4ALDH1A1VCAM1 | |
| SCHEMBL3633645 | 0.89 | TSHR (0.52) | TSHRMAPK1CYP3A4ALDH1A1VCAM1 | |
| SCHEMBL31592017 | 0.89 | TSHR (0.52) | TSHRMAPK1CYP3A4ALDH1A1VCAM1 | |
| SCHEMBL772624 | 0.89 | CYP1A2 (0.48) | TSHRMAPK1CYP3A4ALDH1A1PPIA | |
| SCHEMBL5068830 | 0.87 | PPIA (0.47) | TSHRMAPK1CYP3A4ALDH1A1PPIA | |
| SCHEMBL29586844 | 0.87 | PPIA (0.47) | TSHRMAPK1CYP3A4ALDH1A1PPIA | |
| SCHEMBL80032 | 0.87 | PPIA (0.47) | TSHRMAPK1CYP3A4ALDH1A1PPIA | |
| SCHEMBL358890 | 0.87 | TSHR (0.50) | TSHRMAPK1CYP3A4ALDH1A1VCAM1 | |
| SCHEMBL16013560 | 0.87 | TSHR (0.50) | TSHRMAPK1CYP3A4ALDH1A1VCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112851493-B | Preparation method of 2,4, 5-trifluoro phenylacetic acid | 台州臻挚生物科技有限公司 | 2022-09-06 | — | — | CN | claimed |
| WO-2022099439-A1 | PREPARATION METHOD FOR 2,4,5-TRIFLUOROPHENYLACETIC ACID | 杭州臻挚生物科技有限公司 | 2022-05-19 | — | — | WO | claimed |
| CN-112851493-A | Preparation method of 2,4, 5-trifluorophenylacetic acid | 杭州臻挚生物科技有限公司 | 2021-05-28 | — | — | CN | claimed |
| US-12391663-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-19 | — | — | US | disclosed |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-08 | — | — | US | disclosed |
| CN-117820076-A | Method for preparing 2, 6-dichlorotoluene by micro-channel reactor | 盐城师范学院 | 2024-04-05 | — | — | CN | disclosed |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-03-14 | — | — | US | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| CN-117242060-A | Isoindolinone compounds | 蒙特罗萨医疗公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-4278014-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | Monte Rosa Therapeutics, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-4277901-A1 | ISOINDOLINONE COMPOUNDS | Monte Rosa Therapeutics, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| WO-2002032422-A2 | EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
| EP-0706524-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 5- 2-(4-(BENZOISOTHIAZOL-3-YL)-PIPERAZIN-1-YL)ETHYL]-6-CHLORO-1,3-DIHYDRO-INDOL-2-ONE | PFIZER INC. (US) | 1996-04-17 | — | — | EP | disclosed |
| WO-1995000510-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 5-[2-(4-(BENZOISOTHIAZOL-3-YL)-PIPERAZIN-1-YL)ETHYL]-6-CHLORO-1,3-DIHYDRO-INDOL-2-ONE | PFIZER INC. (US) | 1995-01-05 | — | — | WO | disclosed |
| US-5359068-A | Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one | PFIZER INC. (US) | 1994-10-25 | — | — | US | disclosed |
| US-4532350-A | Process for the selective preparation of meta-chloroanilines | RHONE-POULENC AGROCHIMIE (FR) | 1985-07-30 | — | — | US | disclosed |
| US-4418213-A | HYDRODEHALOGENATION LEWIS ACID AND NOBLE METAL CATALYSTS | RHONE-POULENC AGROCHIMIE (FR) | 1983-11-29 | — | — | US | disclosed |
| US-4351959-A | Process for preparation of anilines substituted by chlorine in the meta-position | RHONE-POULENC AGROCHIMIE (FR) | 1982-09-28 | — | — | US | disclosed |
| US-4340759-A | Process for the preparation of anilines substituted by chlorine in the meta-position | RHONE-POULENC AGROCHIMIE (FR) | 1982-07-20 | — | — | US | disclosed |
| US-4324914-A | Process for preparation of anilines substituted by chlorine in the meta-position | RHONE-POULENC AGROCHIMIE (FR) | 1982-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391663-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | TSHR 1114/4885MAPK1 3281/4885CYP3A4 684/4885 |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | TSHR 1114/4885MAPK1 3281/4885CYP3A4 684/4885 |
| US-11912682-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | TSHR 1114/4885MAPK1 3281/4885CYP3A4 684/4885 |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MYC, MYCBP, GSPT1 | TSHR 2333/4885MAPK1 2937/4885CYP3A4 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.